Literature DB >> 17278999

Neuropathologic features of frontotemporal lobar degeneration with ubiquitin-positive inclusions with progranulin gene (PGRN) mutations.

Keith A Josephs1, Zeshan Ahmed, Omi Katsuse, Joseph F Parisi, Bradley F Boeve, David S Knopman, Ronald C Petersen, Peter Davies, Ranjan Duara, Neill R Graff-Radford, Ryan J Uitti, Rosa Rademakers, Jennifer Adamson, Matthew Baker, Michael L Hutton, Dennis W Dickson.   

Abstract

Frontotemporal lobar degeneration is heterogeneous; cases with tau- and synuclein-negative, ubiquitin-positive neuronal inclusions are the most common, and some have mutations in the gene for progranulin (PGRN). The purpose of this study was to determine whether there were distinctive clinical and neuropathologic features of frontotemporal lobar degeneration with ubiquitin-positive inclusions with PGRN mutations. A retrospective review of medical records and semiquantitative neuropathologic analysis was performed on 18 PGRN(+) and 24 PGRN(-) cases. Clinically, PGRN(+) cases had more frequent language impairment and parkinsonism. Pathologically, PGRN(+) cases had smaller brains, more marked global atrophy, and more frontal atrophy. There was no difference in the frequency of hippocampal sclerosis. The pathology of PGRN(+) cases was relatively homogeneous, whereas PGRN(-) cases were more heterogenous. PGRN(+) cases had greater density of cortical ubiquitin-immunoreactive lesions, especially dystrophic neurites in layer II. Intranuclear inclusions were present in all PGRN(+) and 42% of PGRN(-) cases. The results suggest that frontotemporal lobar degeneration with ubiquitin-positive inclusions due to PGRN mutations has several characteristic features, including ubiquitin-immunoreactive neuritic pathology in superficial cortical layers and neuronal intranuclear inclusions. On the other hand, there is no histopathologic feature or combination of features that is pathognomonic. Neuronal intranuclear inclusions are virtually always present, but they can be detected in PGRN(-) cases.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17278999     DOI: 10.1097/nen.0b013e31803020cf

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  74 in total

1.  Hippocampal sclerosis in Lewy body disease is a TDP-43 proteinopathy similar to FTLD-TDP Type A.

Authors:  Naoya Aoki; Melissa E Murray; Kotaro Ogaki; Shinsuke Fujioka; Nicola J Rutherford; Rosa Rademakers; Owen A Ross; Dennis W Dickson
Journal:  Acta Neuropathol       Date:  2014-11-04       Impact factor: 17.088

2.  Functional genomic analyses identify pathways dysregulated by progranulin deficiency, implicating Wnt signaling.

Authors:  Ezra Y Rosen; Eric M Wexler; Revital Versano; Giovanni Coppola; Fuying Gao; Kellen D Winden; Michael C Oldham; Lauren Herl Martens; Ping Zhou; Robert V Farese; Daniel H Geschwind
Journal:  Neuron       Date:  2011-09-21       Impact factor: 17.173

Review 3.  TAR DNA-binding protein 43 in neurodegenerative disease.

Authors:  Alice S Chen-Plotkin; Virginia M-Y Lee; John Q Trojanowski
Journal:  Nat Rev Neurol       Date:  2010-03-16       Impact factor: 42.937

4.  Imaging correlates of pathology in corticobasal syndrome.

Authors:  J L Whitwell; C R Jack; B F Boeve; J E Parisi; J E Ahlskog; D A Drubach; M L Senjem; D S Knopman; R C Petersen; D W Dickson; K A Josephs
Journal:  Neurology       Date:  2010-11-23       Impact factor: 9.910

5.  Prominent phenotypic variability associated with mutations in Progranulin.

Authors:  Brendan J Kelley; Wael Haidar; Bradley F Boeve; Matt Baker; Neill R Graff-Radford; Thomas Krefft; Andrew R Frank; Clifford R Jack; Maria Shiung; David S Knopman; Keith A Josephs; Sotirios A Parashos; Rosa Rademakers; Mike Hutton; Stuart Pickering-Brown; Jennifer Adamson; Karen M Kuntz; Dennis W Dickson; Joseph E Parisi; Glenn E Smith; Robert J Ivnik; Ronald C Petersen
Journal:  Neurobiol Aging       Date:  2007-10-18       Impact factor: 4.673

6.  Voxel-based morphometry patterns of atrophy in FTLD with mutations in MAPT or PGRN.

Authors:  J L Whitwell; C R Jack; B F Boeve; M L Senjem; M Baker; R Rademakers; R J Ivnik; D S Knopman; Z K Wszolek; R C Petersen; K A Josephs
Journal:  Neurology       Date:  2009-03-03       Impact factor: 9.910

7.  Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration.

Authors:  Nigel J Cairns; Eileen H Bigio; Ian R A Mackenzie; Manuela Neumann; Virginia M-Y Lee; Kimmo J Hatanpaa; Charles L White; Julie A Schneider; Lea Tenenholz Grinberg; Glenda Halliday; Charles Duyckaerts; James S Lowe; Ida E Holm; Markus Tolnay; Koichi Okamoto; Hideaki Yokoo; Shigeo Murayama; John Woulfe; David G Munoz; Dennis W Dickson; Paul G Ince; John Q Trojanowski; David M A Mann
Journal:  Acta Neuropathol       Date:  2007-06-20       Impact factor: 17.088

Review 8.  Neurodegenerative dementia and parkinsonism.

Authors:  A Gabelle; F Portet; C Berr; J Touchon
Journal:  J Nutr Health Aging       Date:  2010-01       Impact factor: 4.075

9.  Clinical, neuropathological and genotypic variability in SNCA A53T familial Parkinson's disease. Variability in familial Parkinson's disease.

Authors:  K Markopoulou; D W Dickson; R D McComb; Z K Wszolek; L Katechalidou; L Avery; M S Stansbury; B A Chase
Journal:  Acta Neuropathol       Date:  2008-04-04       Impact factor: 17.088

Review 10.  Parkinson's disease and parkinsonism: neuropathology.

Authors:  Dennis W Dickson
Journal:  Cold Spring Harb Perspect Med       Date:  2012-08-01       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.